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Three  types of human  interferon  (Hu  IFN)  have  to  date  been  characterized  in 
terms of physicochemical properties and serology (1).  Hu  IFN-a and  -fl are mainly 
produced  by  leukocytes  and  fibroblasts,  respectively,  and  are  pH  2  stable  but 
antigenically distinct  (2,  3).  Hu  IFN-T, produced by lymphocytes  (4,  5)  and T  cell 
clones  (6,  7)  during mitogenic or specific antigenic stimulation,  is pH  2  labile and 
shows no antigenic cross-reactivity with a  or fl (5). There are also differences in cross 
species reactivity between the IFN types: a-IFN is active not only in homologous cells 
but in other mammalian species, whereas 7-IFN is more strictly species specific (8, 9). 
However, we have found that when lymphocytes from individuals who have recently 
received  influenza  vaccine  are  stimulated  in  vitro  with  this  virus,  a  novel  IFN  is 
produced that  is pH  2  labile, but  is neutralized by an antiserum  to a-IFN and has 
activity on heterologous cells. This pH 2-labile a-IFN resembles an IFN that has been 
found in the serum of patients with systemic lupus erythematosus (SLE)  (10). 
Materials  and  Methods 
Vaccination of Volunteers.  Volunteers were vaccinated intramuscularly with MFV Ject (Insti- 
tute Merieux, Lyon, France) containing a mixture of 400 IU of the following influenza viruses: 
A/Tex/77 (HaN2), A/USSR/92/77  (HIN1), and B/HK/8/73. 
Cell Separation and Culture.  Peripheral blood mononuclear cells (PBM) were separated from 
heparinized  venous  blood  samples  by  centrifugation  over  Ficoll-Hypaque.  10  PBM  were 
cultured at 10e/ml in upright plastic flasks (3013; Falcon Labware, Oxnard, CA) in bicarbonate- 
buffered RPM1  1640 medium with added 10 mM Hepes buffer and 10% AB human serum. To 
obtain optimal stimulation of vaccinated volunteers, PBM were stimulated with a mixture of 
equal  proportions of sucrose  density gradient-purified influenza  viruses A/JAP(H2Nz),  A/ 
X31(H3N2),  and  A/BRAZIL (H1Na)  at a  final concentration for the mixture of 1.2 pg/ml. 
After 4 and 6 d  in vitro stimulation, supernatants were sampled and aliquots were stored at 
-70°C until assayed. After sampling the volume of the cultures was made up by addition of 
fresh medium sampling. 
Interferon Assays.  Interferon was measured as the reduction of viral (Semliki Forest virus) 
RNA synthesis in WISH cells (Flow Laboratories, Irvine, United Kingdom [UK]), MDBK cells 
(Flow Laboratories) or V3 monkey kidney cells (11),  and in each experiment IFN activity in 
supernatants was compared with a  laboratory standard calibrated against British Reference 
Standard 69/19 (National Institute for Biological Standards and Controls London, UK). 
Characterization of IFNActivity in Supernatants.  The antiserum to a-IFN was prepared by Dr. 
K.  H.  Fantes,  Wellcome Research  Laboratories, Beckenham,  UK.  A  steer was  repeatedly 
immunized with purified Hu  IFN-a prepared in Namalwa cells with and without  Freund's 
complete adjuvant.  1 ml of this antiserum neutralized 106 IU of HU IFN-a. IFN titers in an 
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aliquot of supernatant were determined; for neutralization studies the antiserum was added in 
the appropriate quantity to neutralize this IFN and incubated for 4 h  at room temperature 
before assaying. Supernatants were left at pH 7 or acidified to pH 2 for 20 h at 4°C. 
c~-IFN Controls.  Purified Hu IFN-a derived from Namalwa cells induced by Sendai virus 
was used as a control. This IFN is known to contain at least eight subtypes of cMFN (12) and 
had a specific activity of 2.8 X  l0  s U/mg protein. 
Results 
PBM  were  separated  from  peripheral  blood  samples  taken  at  intervals  after 
vaccination  from  a  normal  volunteer  and  were  cultured  in  vitro  with  or  without 
influenza virus. In all cultures with the virus, blastogenic transformation and prolif- 
eration of lymphocytes occurred. Typically, the 125Iododeoxyuridine incorporation in 
unstimulated cultures after 6  d  in vitro was  <100  cpm  and  in influenza-stimulated 
cultures  was  >3,000  cpm/105  cells. Table  I  shows  the  characterization of the  IFN 
present in samples taken at the 4th or 6th d  of in vitro culture of PBM with influenza 
virus. The PBM  cultures from four volunteers were set up  7 d  after vaccination. No 
IFN was produced in unstimulated cultures. 
As shown in Table I, the IFN produced in the influenza-stimulated cultures was in 
all cases strongly inactivated by pH 2 treatment for 20 h  but was also neutralized by 
an  antiserum  to  Hu  IFN-c~.  However,  PBM  cultures  set  up  at  the  same  time  and 
stimulated with the mitogen concanavalin A  (Con A), an inducer of y-IFN, produced 
a  pH  2-labile IFN  that  was  not  significantly neutralized  by  the  a-IFN  antibody. 
Throughout  this series of experiments, PBM  from donor GH  failed to produce high 
levels of IFN when  stimulated with  Con  A.  Controls  of e~-IFN, induced  by Sendai 
virus in Namalwa cells, Hu IFN-~N, and known to contain at least eight subtypes of 
c~-IFN (12), were set up with each experiment and showed  no inactivation with the 
pH 2 treatment, but total neutralization with the c~ antiserum  (Table I). 
Further  experiments  showed  us  that  this  acid-labile a-IFN was  the predominant 
IFN produced in influenza-stimulated cultures from  the four vaccinated individuals 
set up at various times after vaccination. So far we have examined cultures up to 49 
TABLE  I 
IFN Activity Produced by Mitogen or Antigen Stimulation 6  7 Days 
Postvaccination 
Volunteer  Stimulus 
Treatment  with 
pH  7  pH 2  Control  Anli-c~ 
20 h  20 h  calf serum  serum 
U/m/ 
PB  Flu  1,450  66  1,750  22 
BA  Con A  125  <8  560  450 
BA  Flu  4,000  <8  4,500  540 
MY  Con A  428  <8  350  300 
MY  Flu  1,345  30  1,658  440 
GH  Con A  6  0  3  2 
C-H  Flu  1,715  27  3,517  340 
controls  603  540  553  <8 
580  600  580  <8 
The IFN activity in the supernatants was assayed on WISH ceils as described in Materials 
and Methods.  Supernatants  from cultures of PBM from PB were harvested after 4 d  of in 
vitro culture,  and  from BA,  MY, and  GH after 6  d.  a-IFN controls  consisted  of highly 
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d  postvaccination. A  summary of all the data obtained in this experimental series is 
shown in Table II in terms of mean percentage inactivation by pH 2 or neutralization 
by anti-a treatment. It is clear that influenza-induced IFN is strongly neutralized by 
the anti-a serum (mean neutralization, 77%),  whereas Con A  was not (mean neutral- 
ization, 21%), but both activities are pH 2 labile (95 and 97%,  respectively). However, 
the a  antiserum did cause a slight neutralization of the Con A-induced IFN activity; 
this may reflect experimental error, low-level cross-reactivity of this antibody for Hu 
IFN y, or the fact that Con A  induced a small amount of acid labile a-IFN as well as 
y-IFN. The variability seen in the neutralization of the influenza supernatants by the 
a  antibody may reflect a lower affinity of the antibody for this IFN, or alternatively, 
variable amounts of pH 2-labile 7-IFN may be produced during this in vitro immune 
response. 
The pH 2-labile IFN produced by PBM stimulated with influenza antigen in vitro 
also differed  from conventional y-IFN  in terms of its cross-species specificity  (Table 
III).  This  IFN had greater activity on monkey and bovine cells  than the IFN  from 
Con A-induced  supernatants,  although it  did  not show the same cross-reactivity as 
TABLE  II 
Summary of IFN Characterization 
Type of sample 
Mean  percent  reduction  of ti- 
Number 
ter -4- SD after treatment  with 
of sam- 
ples  Antiserum  to 
tested  a-IFN  pH 2 
Con A-stimulated  PBM supernatant  15  21  :tz21"  97 +  3 
Influenza  virus-stimulated  PBM super-  20  77 +- 18"  95 ::t: 3 
natant 
a  control  9  95 -  8  11  -+  13 
* The  difference  between  these  two  groups  was  found  to  be  highly  significant  by  the 
Wilcoxon  two-sample rank sum test  (P <  0.0001). 
TABLE  III 
Cross-species Reactivity of lnfluenza and Con A-Induced IFN Activity 
Time  IFN activity  IFN activity 
Stimulus  in  on human  Volunteer  after vac- 
vitro  cination  Human  Monkey  Bovine  cells after 
(WISH)  (V3)  (MDBK)  20 h  pH 2 
d  U/ml 
BA  Con A  24  896  65  47 
BA  Con A  7  1,383  28  <10 
PB  Con A  39  3,083  85  <  10 
GH  Con A  7  98  <10  <10 
MY  Con A  7  1,240  35  <10 
BA  Flu  24  3,850  843  323 
GH  Flu  7  1,870  470  160 
MY  Flu  7  820  190  143 
PB  Flu  39  !,463  860  650 
BA  Flu  7  5,750  570  193 
a  controls  909  1,000  4,230 
200  270  740 
U/ml 
40 
42 
85 
23 
5 
142 
27 
32 
122 
<8 
ND* 
ND 
Interferon activity in the supernatants was assayed on WISH, V3, and 
assays. 
* Not determined. 
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conventional c~-IFN. Hu IFNa-N had equal activity on human and monkey cells and 
three-  to  fourfold  more  activity  on  bovine  cells,  as  shown  in  Table  III.  We  also 
investigated  the  heat  lability  of the  different  IFN activities.  Con A- and  influenza- 
stimulated  PBM  supernatants  were  almost  completely  inactivated  by  a  15-rain 
incubation  at  56°C  (mean  inactivation  87 and 90%, respectively)  whereas  Hu  IFN- 
c~N was not significantly inactivated  (mean inactivation,  17%). 
Discussion 
The  unusual  IFN activity  described  in  this  paper  probably  represents  an  as  yet 
uncharacterized  subtype of ~-IFN. There  are  10 or more genes coding for different 
a-IFN (13), the products of which are not all clearly defined in terms of physicochem- 
ical properties. Acid-stable c~-IFN is produced by leukocytes challenged with a variety 
of viral and nonviral stimuli  (1, 8,  14,  15)  and in vitro production of acid-labile IFN 
has been briefly mentioned in two previous studies  (9,  16), but no detailed character- 
ization  has  been  done.  In vivo acid-labile  ~-IFN has  been  described  in  the  sera  of 
mice infected  with  murine cytomegalovirus (17,  and  Dr. Jane Allen,  personal com- 
munication)  and in patients with SLE (10). 
We do not know what subtype of blood mononuclear cell produces this acid-labile 
~-IFN.  Ennis  and  Meager  (18)  have reported  the production  of Hu  IFN-y in an  in 
vitro  immune  response  to  influenza  virus  in  vaccinated  individuals,  but  there  are 
significant  differences between  their  system and ours.  In their experiments  lympho- 
cytes were stimulated  with  influenza virus in such a  way as to generate cytotoxic T 
cells (19), whereas our cultures are known to produce helper T  cells (20, 21). It will be 
of interest  to see whether the production of different IFN types is related to different 
effector T  cell subtypes; such experiments are currently underway. 
Summary 
We have described  in  this  paper  a  novel  human  interferon  (IFN)  with  antigenic 
and cross-species reactivity of a-IFN and physicochemical properties  of y-IFN. This 
IFN is  produced by normal  peripheral  blood mononuclear cells  during  an immune 
response  but  has  also  been  associated  with  autoimmune  disease  (10).  The  system 
described  here  will  be  useful  in  elucidating  the  biological  significance  and  cell  of 
origin of this IFN. 
We thank Dr. K. H. Fantes, Wellcome Research Laboratories, UK, for the antiserum  to Hu 
IFN-a, and Dr. J. Skehel,  National Institute for Medical Research, UK, for the influenza virus 
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